Nasus Pharma To Present Positive Clinical Results From Recent studies of FMXIN002 (NS002) Intranasal Epinephrine at the 2025 AAAAI Annual Meeting
Nasus Pharma Ltd. ("Nasus Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on developing ...
TSX Penny Stock Highlights For February 2025
As 2025 unfolds, the Canadian market has seen a modest rise, with the TSX up by 3%, amidst stabilizing yields and contained inflation both in Canada and the U.S. Despite growth concerns and potential ...